| Note: This medical device record is a PMA supplement. A supplement may have changed the device description/function or indication from that approved in the original PMA. Be sure to look at the original PMA record for more information. |
| |
| Device | SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valve System |
|---|
| Generic Name | Aortic valve, prosthesis, percutaneously delivered |
|---|
| Applicant | EDWARDS LIFESCIENCES, LLC.
One Edwards Way
Irvine, CA 92614 |
|---|
| PMA Number | P140031 |
|---|
| Supplement Number | S125 |
|---|
| Date Received | 11/18/2020 |
|---|
| Decision Date | 05/13/2021 |
|---|
| Product Code |
NPT |
| Docket Number | 21M-0473 |
|---|
| Notice Date | 05/20/2021 |
|---|
| Advisory Committee |
Cardiovascular |
|---|
| Supplement Type | Panel Track |
|---|
| Supplement Reason | Labeling Change - Indications/instructions/shelf life/tradename |
|---|
| Expedited Review Granted? | No |
|---|
| Combination Product | No |
|---|
Approval Order Statement
Approval for the Edwards SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valve System. The device is indicated for patients with symptomatic heart disease due to failing (stenosed, insufficient, or combined) of a surgical or transcatheter bioprosthetic aortic valve, a surgical bioprosthetic mitral valve, or a native mitral valve with an annuloplasty ring who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality >= 8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical co-morbidities unmeasured by the STS risk calculator). |
| Approval Order | Approval Order |
|---|
| Summary | Summary of Safety and Effectiveness |
|---|
| Labeling | Labeling
Labeling Part 2 |
|---|
| Post-Approval Study | Show Report Schedule and Study Progress |
|---|
|
|
